Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06878261 · ClinicalTrials.gov registry record · Phase 3

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
990
Enrollment target
20
Study locations

NCT06878261 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 990 participants, above the 624-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (59% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06878261, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
990 participants
Enrollment target
20
Study locations

Study Summary

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Conditions Studied

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • OTHER Placebo
  • BIOLOGICAL Tezepelumab

Study Locations (20)

Florida

  • Research Site - Bay Pines
  • Research Site - Boynton Beach
  • Research Site - Clearwater
  • Research Site - Fleming Island
  • Research Site - Jacksonville
  • Research Site - Leesburg
  • Research Site - Margate
  • Research Site - Miami
  • Research Site - Miami
  • Research Site - Miami Lakes

California

  • Research Site - Inglewood
  • Research Site - Los Angeles
  • Research Site - Palo Alto
  • Research Site - Redding
  • Research Site - San Diego

Arizona

  • Research Site - Phoenix
  • Research Site - Scottsdale

Alabama

  • Research Site - Cullman

Connecticut

  • Research Site - New Britain

Delaware

  • Research Site - Wilmington

Trial Details

FieldValue
Enrollment Target 990 participants
Start Date 2025-03-25
Est. Completion 2029-06-05
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06878261

The ClinicalTrials.gov registry entry for NCT06878261 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 990 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 624-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (59% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06878261 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT06878261 about?

NCT06878261 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)". A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

What is the current status of trial NCT06878261?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 990 participants. The study started on 2025-03-25. Estimated completion is 2029-06-05.

What conditions does trial NCT06878261 study?

This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).

What interventions are being tested in trial NCT06878261?

The interventions under investigation include: Placebo (OTHER), Tezepelumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT06878261?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06878261 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Obstructive Pulmonary Disease (COPD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Obstructive Pulmonary Disease (COPD)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.